The short version of Nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
=== Daily Telegraph libel case === On 22 April 2003, The Daily Telegraph published news articles and comment describing documents found by its reporter David Blair in the ruins of the Iraqi Foreign Ministry. The documents purported to be records of meetings between Galloway and Iraqi intelligence agents, and they stated that he had received £375,000 per year from the proceeds of the Oil-for-Food Programme. Galloway sued the newspaper for libel by November 2003, and the case was heard in the High Court on 14 November 2004. On 2 December, Justice David Eady ruled that the story had been "seriously defamatory", and that The Daily Telegraph was "obliged to compensate Mr Galloway ... and to make an award for the purposes of restoring his reputation." Galloway was awarded damages of £150,000 plus, after a failed appeal in 2006, legal costs of about £2 million. Both sides regarded the libel case as an important test of the Reynolds qualified-privilege defence. The Daily Telegraph did not attempt to claim justification (where the defendant seeks to prove the truth of the defamatory reports): "It has never been the Telegraph's case to suggest that the allegations contained in these documents are true". The newspaper argued that it acted responsibly as the allegations it reported were of sufficient public interest to outweigh the damage caused to Galloway's reputation.
=== 100% fruit juice === Research suggests that 100% fruit juice is not associated with an increased risk of diabetes. A 2018 review concluded that 100% fruit juice increases the risk of tooth decay in children, but there is "no conclusive evidence that consumption of 100% fruit juice has adverse health effects." A 2025 umbrella review concluded that "the balance of evidence does not support the exclusion of 100% juice from food-based guides to healthy eating".
On 19 June, Nasrallah stated that a Hezbollah invasion of the Galilee "remains on the table" and alleged that the government of Cyprus was allowing Israeli forces to operate within its country and thus made Cyprus a legitimate target for Hezbollah strikes. Cypriot president Nikos Christodoulides denied that Cyprus was taking sides in the conflict. On 30 June, Israeli officials reported 18 IDF soldiers were wounded by a drone attack on the Golan Heights. The inability of Israelis to return to settlements and homes in the north of the country led to Antony Blinken stating that Israel had effectively "lost sovereignty in the northern quadrant of its country". On 3 July, senior Hezbollah field commander Mohammed Nasser was killed in an Israeli airstrike in Tyre, and in response Hezbollah fired 100 rockets at IDF positions. The following day, it fired 200 more rockets into Israel. On 9 July, an Israeli airstrike on the Beirut–Damascus highway in Syria killed two Hezbollah members, and Hezbollah fired 40 rockets at the Golan Heights. A week later, at least two people were wounded in an Israeli drone attack in Lebanon, and Hezbollah rocket strikes in Kiryat Shmona damaged residential buildings. On 22 July, drones from Lebanon were intercepted by Israeli forces, and a Hezbollah rocket strike injured two soldiers in northern Israel. The following day and in response, Israel launched artillery strikes on southern Lebanon, Hezbollah launched rocket strikes in northern Israel, and Israeli warplanes and artillery struck southern Lebanon.
Sources: en.wikipedia.org
Aerobic metabolism is up to 15 times more efficient than anaerobic metabolism (which yields 2 molecules of ATP per 1 molecule of glucose). However, some anaerobic organisms, such as methanogens are able to continue with anaerobic respiration, yielding more ATP by using inorganic molecules other than oxygen as final electron acceptors in the electron transport chain. They share the initial pathway of glycolysis but aerobic metabolism continues with the Krebs cycle and oxidative phosphorylation. The post-glycolytic reactions take place in the mitochondria in eukaryotic cells, and in the cytoplasm in prokaryotic cells. Although plants are net consumers of carbon dioxide and producers of oxygen via photosynthesis, plant respiration accounts for about half of the CO2 generated annually by terrestrial ecosystems.
p A + q B ⇌ ApBq The study of these complexes is important for supramolecular chemistry and molecular recognition. The objective of these studies is often to find systems with a high binding selectivity of a host (receptor) for a particular target molecule or ion, the guest or ligand. An application is the development of chemical sensors. Finding a drug which either blocks a receptor, an antagonist which forms a strong complex the receptor, or activate it, an agonist, is an important pathway to drug discovery.
==== Infectious diseases ==== A 2021 meta-analysis found that "vitamin D supplementation was safe and overall reduced the risk of ARI […] although the risk reduction was small". In general, vitamin D functions to activate the innate and dampen the adaptive immune systems with antibacterial, antiviral and anti-inflammatory effects. Low serum levels of vitamin D appear to be a risk factor for tuberculosis. However, supplementation trials showed no benefit.
Sources: en.wikipedia.org
=== Side reactions === The three main side reactions that produce impurities have in common that they decompose urea. Urea hydrolyzes back to ammonium carbamate in the hottest stages of the synthesis plant, especially in the stripper, so residence times in these stages are designed to be short. Biuret is formed when two molecules of urea combine with the loss of a molecule of ammonia.
== Adverse effects == Most of the comparatively few fatal incidents associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially alcohol. A common adverse effect resulting from psilocybin mushroom use involves "bad trips" or panic reactions, in which people become anxious, confused, agitated, or disoriented. Accidents, self-injury, or suicide attempts can result from serious cases of acute psychotic episodes. No studies have linked psilocybin with birth defects, but it is recommended that pregnant women avoid its usage.
=== Foods === Sucrose esters are used as food additives in a variety of food. European Parliament and Council Directive No 95/2/EC limited the use of sucrose esters under E 473 in each kind of food. No longer in force, Date of end of validity: 20/01/2010; Repealed by 32008R1333 .
=== Fuels === The dominant use of alkanes is as fuels. Propane and butane, easily liquified gases, are commonly known as liquified petroleum gas (LPG). From pentane to octane the alkanes are highly volatile liquids. They are used as fuels in internal combustion engines, as they vaporize easily on entry into the combustion chamber without forming droplets, which would impair the uniformity of the combustion. Branched-chain alkanes are preferred as they are much less prone to premature ignition, which causes knocking, than their straight-chain homologues. This propensity to premature ignition is measured by the octane rating of the fuel, where 2,2,4-trimethylpentane (isooctane) has an arbitrary value of 100, and heptane has a value of zero. Apart from their use as fuels, the middle alkanes are also good solvents for nonpolar substances. Alkanes from nonane to, for instance, hexadecane (an alkane with sixteen carbon atoms) are liquids of higher viscosity, less and less suitable for use in gasoline. They form instead the major part of diesel and aviation fuel. Diesel fuels are characterized by their cetane number, cetane being an old name for hexadecane. However, the higher melting points of these alkanes can cause problems at low temperatures and in polar regions, where the fuel becomes too thick to flow correctly.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.